

NEXT SCIENCE®

Next Science receives EPA approval for Surface Disinfectant

Sydney, Australia, Wednesday, 8 April 2020: Next Science Limited (ASX:NXS) is delighted to advise that it has received notification from the US Environmental Protection Agency (**EPA**) that its Hospital Cleaner Surface Disinfectant (**LMN8**) has been accepted for registration with clearance for inclusion on the product labelling of a Claim for effectiveness against biofilm.

Next Science is one of only 3 companies who have been awarded that Claim by the EPA at this time. Further, Next Science's Surface Disinfectant is the only EPA approved product with a biofilm Claim that is non-toxic to humans with safety glasses the only required form of personal protection equipment (PPE).

The EPA's acceptance of the Surface Disinfectant for registration is a significant milestone for Next Science in that it reflects more than six years work to gain the EPA's approval for a biofilm standard to be used as a product claim.

Unlike bleach and many other disinfectants in the market, Next Science's Surface Disinfectant is a non-toxic product which uses Next Science's patented Xbio technology to eliminate biofilm based (and free floating) bacteria. Xbio's effectiveness against many types of bacteria including *Golden Staph* and *E. coli* (a common cause of diarrhea) has been validated by extensive clinical testing, multiple FDA clearances and more than 130,000 patient treatments since 2017. Through third party laboratory testing, Next Science has not identified any evidence of bacterial resistance to its Xbio technology.

Negotiations with potential partners for commercialisation of the Surface Disinfectant are continuing.

Managing Director, Judith Mitchell, commented: "Receipt of EPA registration of our Hospital Cleaner Surface Disinfectant LMN8 now gives us the opportunity to more widely assist hospitals and communities in the fight against infection."

Approved by the Chair of Next Science Limited.

Further information:

Judith Mitchell

Managing Director, Next Science Limited
Phone: +61 2 9375 7989
Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory
Phone: +61 400 248 080
Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. Website: www.nextscience.com.